Home>>Signaling Pathways>> Obesity, Appetite Control & Diabetes>> Obesity>>Glucocerebrosides (Gaucher's spleen)

Glucocerebrosides (Gaucher's spleen) (Synonyms: Ganglioside GL1a, Gaucher cerebroside, GluCers (Gaucher's spleen), Glucocerebrosides, Glucosylceramides (Gaucher's spleen))

Catalog No.GC43768

Glucocerebrosides are formed by the tethering of glucose to a ceramide by glucosylceramide synthase.

Products are for research use only. Not for human use. We do not sell to patients.

Glucocerebrosides (Gaucher's spleen) Chemical Structure

Cas No.: 85305-87-9

Size Price Stock Qty
500μg
$160.00
In stock
1mg
$286.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Glucocerebrosides are formed by the tethering of glucose to a ceramide by glucosylceramide synthase. They are present in neuronal and non-neuronal mammalian tissues and are found at low quantities in a large number of plant species. Glucocerebrosides are precursors in the synthesis of lactosylceramides and gangliosides. Increased levels of glucocerebrosides are associated with obesity-induced insulin resistance in mice and with neuronal deficits observed in neuronopathic Gaucher disease. This product is a mixture of glucocerebrosides, with variable ceramide chain lengths, isolated from a spleen of a human with Gaucher's disease.

Reviews

Review for Glucocerebrosides (Gaucher's spleen)

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Glucocerebrosides (Gaucher's spleen)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.